TimesSquare Capital Management LLC Purchases New Shares in Vera Therapeutics, Inc. $VERA

TimesSquare Capital Management LLC purchased a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 252,462 shares of the company’s stock, valued at approximately $12,785,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after buying an additional 236 shares during the period. Quantbot Technologies LP purchased a new stake in Vera Therapeutics in the second quarter worth $51,000. Tower Research Capital LLC TRC increased its stake in Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after purchasing an additional 2,757 shares during the period. AlphaQuest LLC grew its position in shares of Vera Therapeutics by 414.2% during the 3rd quarter. AlphaQuest LLC now owns 5,214 shares of the company’s stock worth $152,000 after buying an additional 4,200 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Vera Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock worth $157,000 after buying an additional 639 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Insider Transactions at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 22,951 shares of the firm’s stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $44.05, for a total value of $1,010,991.55. Following the completion of the transaction, the chief executive officer directly owned 235,244 shares in the company, valued at $10,362,498.20. This trade represents a 8.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider William D. Turner sold 2,187 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $91,810.26. Following the completion of the transaction, the insider owned 45,313 shares of the company’s stock, valued at approximately $1,902,239.74. The trade was a 4.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 74,941 shares of company stock valued at $3,096,592. 15.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

VERA has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. Evercore set a $91.00 price target on Vera Therapeutics in a research report on Friday. Wolfe Research raised Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a research report on Wednesday, March 11th. Finally, HC Wainwright raised their price objective on Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Vera Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $79.00.

Vera Therapeutics Price Performance

Shares of NASDAQ VERA opened at $33.25 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. The company has a market cap of $2.39 billion, a PE ratio of -6.00 and a beta of 0.96. The business has a 50-day simple moving average of $39.38 and a two-hundred day simple moving average of $40.74. Vera Therapeutics, Inc. has a fifty-two week low of $18.76 and a fifty-two week high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period last year, the business earned ($0.81) earnings per share. As a group, equities analysts expect that Vera Therapeutics, Inc. will post -5.9 EPS for the current fiscal year.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.